Dr. Sarah Schlesinger appointed to The Medicines Company’s Board of Directors

The Medicines Company  declared that its Board of Directors has appointed Dr. Sarah Schlesinger as a new, independent Director of the Company, effective immediately.

Dr. Schlesinger brings with him more than 20 years working in the field of cellular immunity. She is currently the Chair of The Rockefeller University Hospital’s Institutional Review Board (IRB) and Senior Physician and Associate Professor of Clinical Investigation at The Rockefeller University. Prior to becoming Chair of the hospital’s IRB, Dr. Schlesinger served as Clinical Director of the Laboratory of Molecular Immunology and Clinical Director of The Laboratory of Cellular Immunology and Physiology – the laboratory led by the late Ralph M. Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine. Before joining The Rockefeller University in 2003, Dr. Schlesinger was a scientist at the International AIDS Vaccine Initiative in New York City from 2002 to 2003, and a Research Physician/Pathologist at the Division of Retrovirology at the Walter Reed Army Institute of Research from 1996 to 2002.

Chief Executive Officer, Clive Meanwell, M.D., Ph.D said “Sarah is a valuable addition as we continue to successfully execute on our strategic plan. I know that the Company will benefit from her expertise, insight and experience, and I and the rest of the Board look forward to working with her.”